Geparin-Indar solution for infection. 5000 ME/ml fl. 5 ml No. 1

Geparin-Indar – antitrombotichesky means. Group of heparin.

Indications

• prevention and treatment of thromboembolic diseases and their complications (a sharp coronary syndrome, fibrinferments and embolisms of the main veins and arteries, vessels of a brain, an eye, the I phase of a syndrome of disseminate intravascular coagulation, a constant form of atrial fibrillation with embolization);
• prevention of postoperative venous thromboses and embolisms of a pulmonary artery (in the mode of a low dosage) at the patients who transferred surgical interventions or at those who for other reasons have risk of developing a clotting disease;
• prevention of fibrillation at laboratory researches, dialysis, extracorporal blood circulation, heart surgeries and vessels, direct blood transfusion.

Structure

• active ingredient: heparin sodium;
5000 ME heparin sodium contains
• 1 ml of injection solution;
• other components: benzyl alcohol, sodium chloride, water for injections.

Contraindication

Hypersensitivity to heparin and/or alcohol benzylic, hemophilia, hemorrhagic diathesis, suspicion of geparinindutsirovanny immune thrombocytopenia, a round ulcer of a stomach and duodenum, heavy arterial hypertension, cirrhosis, periods, recently carried out surgical interventions, especially neurosurgical and ophthalmologic, ulcer colitis, malignant new growths, a hemorrhagic stroke (first 2–3 days), craniocereberal injuries, a retinopathy, hemorrhage in eye fabrics, a destructive pulmonary tuberculosis; entsefalomalyation; hemorrhagic pancreatonecrosis; bleedings of any localization (open stomach ulcer, intracranial bleeding), except for the hemorrhage which arose because of an embolic heart attack of lungs (pneumorrhagia) or kidneys (hamaturia); repeated bleedings in the anamnesis regardless of localization; increase in permeability of vessels (for example, at Verlgof's disease); state of shock; the menacing abortion.

Heparin cannot be applied: to the patients who used high doses of alcohol; in the form of intramuscular injections; at sharp and chronic leukoses; aplastic and hypoplastic anemias; at sharp aneurysm of heart and an aorta; when carrying out operations on a head or spinal cord, an eyeball, ears; after carrying out surgeries on sites where development of bleeding is life-threatening the patient; at diabetes, when carrying out epidural anesthesia during childbirth. Conduction anesthesia as use of heparin in rare instances can cause epidural or spinal hematomas is contraindicated to patients to whom apply heparin in the medical purposes when carrying out planned surgeries therefore long or irreversible paralysis can develop.

Side reactions

belong To the most widespread side reactions hemorrhages, increase in level of liver enzymes, reversible thrombocytopenia and various dermatological violations. Also it was reported about isolated cases of generalized allergic reactions, necrosis of skin and a priapism.

from the system of blood: thrombocytopenia of the I type; The II type; epidural and spinal hematomas.

Mental violations depression.

from nervous system: headaches.

by

in the form of jet or faltering intravenous or subcutaneous injections. Before prescribing of medicine it is necessary to define a blood clotting time, the thrombin and activated partial tromboplastinovy time, quantity of platelets. For cultivation of heparin to use only 0.9% sodium chloride solution.

Adult at sharp thrombosis treatment to begin

with intravenous administration 10000–15000 medicine ME Geparin-Indar under control of coagulation of venous blood, the thrombin and activated partial tromboplastinovy time. After that on 5000-10000 ME medicines Geparin-Indar to enter intravenously each 4–6 hours. At the same time the dose at which the blood clotting time is extended by 2.5-3 times, and the activated partial tromboplastinovy time – by 1.5-2 times is considered adequate.

Geparin-Indar to enter

For prevention of sharp thrombosis subcutaneously for 5000 ME each 6–8 hours. At the first phase of a syndrome of disseminate intravascular fibrillation (DVS) at adults heparin to appoint subcutaneously long in a daily dose 2500-5000 ME under control of thrombin time. In 1–2 days prior to medicament withdrawal Geparin-Indar gradually to reduce a daily dose.

during open-heart surgery with connection of the device of extracorporal blood circulation to patients to enter Geparin-Indar in an initial dose not less than 150 ME on 1 kg of body weight. When the procedure lasts less than 60 minutes, to appoint a dose of 300 ME/kg and when the procedure lasts more than 60 minutes, to appoint 400 ME/kg.

Geparin-Indar to enter

With the preventive purpose subcutaneously in a dose 5000 ME in 2 hours prior to operation, then for 5000 ME each 6–8 hours within 7 days.

to

Use during pregnancy or feeding by a breast

Heparin is not contraindicated to

Feature of application

Children

to use Drug to children according to body weight. Not to apply to premature children or newborns. Development of allergic reactions, including toxic is possible, at children 3 years are younger.

Ability to influence speed of response at control of motor transport or other mechanisms

Is not present data on influence of heparin on speed of response at control of motor transport or work with other mechanisms.

At overdose the developing of bleedings is possible

. In insignificant bleedings there can be sufficient a reduction of a dose or the temporary termination of its introduction. In considerable bleedings it is urgent to cancel introduction of heparin and to appoint antidote - 1% protamin sulfate solution (to enter slowly intravenously) from calculation that 1 mg of sulfate of protamin neutralizes 85 ME heparins.

Storage conditions

to Store

in original packing for protection against light at a temperature not above 25 °C.

to Store

out of children's reach.